[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"agoraphobia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:agoraphobia":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,63,88,121,151,182,203,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910",false,"NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","ALL","5 Years","18 Years",{"count":21,"type":22},501,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety Disorder","Anxiety","OCD","Phobia","Agoraphobia","Generalized Anxiety","Generalized Anxiety Disorder","Selective Mutism","Separation Anxiety","Social Anxiety","Social Anxiety Disorder","Panic Disorder","Pediatric Disorders",[44,45,46,47,48,49],"exposure therapy","cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","RECRUITING","2026-05-13",{"date":53,"type":54},"2026-05-14","ACTUAL",{"date":56,"type":54},"2025-11-01",{"date":58,"type":22},"2029-08-01",{"name":60,"class":61},"Bradley Hospital","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":62},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners","65 Years",{"count":72,"type":22},80,[25],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[76,36,40,41,34,77,78],"Anxiety Disorders","Major Depressive Disorder","Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":81,"type":54},"2026-05-05",{"date":83,"type":54},"2025-06-01",{"date":85,"type":22},"2027-08-31",{"name":87,"class":61},"Georgetown University",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":62},"100588517","stepped-versus-stratified-care-for-anxiety-disorders-in-youth-100588517","NCT06942429","Stepped Versus Stratified Care for Anxiety Disorders in Youth","Stepped Versus Stratified Care for Anxiety Disorders in Youth: A Pragmatic Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 8.0 to 17.5 years. Confirmed by the child and\u002For caregiver.\n2. Principal DSM-5-TR anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia. Confirmed by the structured diagnostic interview (DIAMOND-KID). \"Principal\" indicates that the anxiety disorder is judged by the clinician to be in most urgent need of treatment (among potential co-occurring disorders).\n3. Available caregiver who can support the child in treatment. Confirmed by the caregiver.\n4. Child and at least one caregiver can read, write, and communicate in Swedish. Confirmed by the child and\u002For caregiver.\n5. Child (≥13 years) and caregiver have access to a Swedish electronic identification (BankID or Freja eID).\n6. Access to the internet. Confirmed by the child and\u002For caregiver.\n7. Ability to attend in-person CBT sessions at the clinic. Confirmed by the child and\u002For caregiver.\n\nExclusion Criteria:\n\n1. Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises). Confirmed by a specific phobia of this sort being classified as the most functionally impairing anxiety disorder during the structured diagnostic interview (DIAMOND-KID).\n2. Ongoing psychological treatment for an anxiety disorder. Confirmed by the child and\u002For caregiver.\n3. Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder. Confirmed by the assessor through information from the child and\u002For caregiver and\u002For other available sources.\n4. Immediate risk to self or others that require urgent attention, such as suicidality. Confirmed by the assessor through information from the child and\u002For caregiver and other available sources.\n5. The potential participant has a relative (e.g., sibling, cousin) included in the study. Confirmed by the assessor through information from the caregiver and other available sources.","8 Years","17 Years",{"count":98,"type":22},556,[25],"The goal of this clinical trial is to compare stepped care to stratified care as overall healthcare models for children and adolescents aged 8-17 with anxiety disorders. It addresses one main question:\n\n• Is stepped care non-inferior to stratified care in supporting participants to achieve a treatment response?\n\nResearchers will compare two care models:\n\n* Stepped care, where all participants begin with 14 weeks of internet-delivered cognitive behavioral therapy (ICBT) and receive an additional 14 weeks of personalized in-person CBT if needed.\n* Stratified care, where participants are assigned to either 14 weeks of ICBT or 14 weeks of in-person CBT based on clinical complexity, and may also receive additional 14 weeks of in-person CBT if necessary.\n\nParticipants will:\n\n* Be randomly assigned to one of the two care models.\n* Complete a wide range of assessments at baseline, during treatment, and at 4, 8, 12, and 24 months, with the 8-month point as the primary endpoint.\n* Receive either ICBT, in-person CBT, or both, depending on their care model and response to treatment.\n* Participate in ancillary studies involving DNA sampling, cognitive testing, and national registry linkages to help predict treatment response and long-term outcomes.",[40,102,103,41,36,34],"Separation Anxiety Disorder","Specific Phobia",[105,106,107,45,108,109,110,111],"anxiety disorders","children","adolescents","non-inferiority","care models","stepped care","stratified care","2026-02-24",{"date":114,"type":54},"2026-02-27",{"date":116,"type":54},"2025-06-19",{"date":118,"type":22},"2031-03-05",{"name":120,"class":61},"Region Skane",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":62},"100566921","internet-delivered-cognitive-behavioral-intervention-for-youths-with-anxiety-disorders-100566921","NCT06661460","Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Development and Preliminary Evaluation of a New Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders","Inclusion Criteria:\n\n1\\) 8 to \\\u003C18 years of age.\n\n* Confirmed by the child\u002Fcaregiver and subsequently by the medical record system. 2) A principal DSM-5-TR anxiety disorder of specific phobia, separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder or agoraphobia.\n* Confirmed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders - Child and Adolescent Version (DIAMOND-KID).\n\n  3\\) Child and caregiver able to read, write and communicate in Swedish.\n* Confirmed by the child\u002Fcaregiver. 4) An available caregiver who can support the child in treatment.\n* Confirmed by the caregiver. 5) Access to a smartphone, tablet, or laptop\u002Fdesktop device, and the internet.\n* Confirmed by the child\u002Fcaregiver.\n\nExclusion Criteria:\n\n1\\) Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).\n\n* Confirmed by a blood-injection-injury phobia being classified as the principal anxiety disorder as assessed by the DIAMOND-KID.\n\n  2\\) Established or suspected intellectual disability.\n* Confirmed by the caregiver (through previous diagnosis) and\u002For by attending a special needs school for learning difficulties.\n\n  3\\) Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).\n* According to the DIAMOND-KID and\u002For other available sources. 4) Social\u002Ffamilial\u002Feducational difficulties in more immediate need of management than an anxiety disorder.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and\u002For other available sources.\n\n  5\\) Immediate risk to self or others that require urgent attention, such as acute suicidality.\n* Confirmed by the assessor through information from the child\u002Fcaregiver and other available sources.\n\n  6\\) Previous CBT for an anxiety disorder, defined as five or more sessions with a certified CBT therapist within the 12 months prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 7) Ongoing psychological treatment for an anxiety disorder.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 8) Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment.\n* Confirmed by the child\u002Fcaregiver or the medical record system. 9) Participation in user involvement sessions in the present study.\n* Confirmed by the researcher.",{"count":129,"type":22},48,[25],"The goal of this study is to develop a new internet-delivered cognitive behavioral therapy (ICBT) intervention for youths with anxiety disorders based on the best current knowledge about effective cognitive behavioral therapy for the target group, refine the intervention in collaboration with patient and public representatives, and conduct a preliminary evaluation of the treatment effects in an open clinical trial.\n\nThe primary objective of the study is:\n\n1\\. To evaluate the preliminary efficacy of a newly developed ICBT intervention for children and adolescents with anxiety disorders in reducing anxiety severity, as measured by the Pediatric Anxiety Rating Scale (PARS).\n\nSecondary objectives of the study are:\n\n1. To examine the preliminary efficacy (PARS) of the ICBT intervention at 3 months post-treatment.\n2. To examine how youths with anxiety disorders, their caregivers, therapists, and healthcare leadership experience the ICBT intervention.\n3. To examine factors (e.g., age, type of anxiety disorder, presence of depressive symptoms, experiences of ICBT) that predict treatment outcome.\n4. To examine how the ICBT intervention can be improved (e.g., treatment content and technical delivery) for future use.\n\nParticipants will:\n\n* Undergo ICBT treatment for anxiety disorders during 12 weeks\n* Complete questionnaires at multiple time points throughout the study\n* Participate in follow-ups post-treatment and 3 months post-treatment\n* A selection of participants will also be invited to focus group interviews with the aim to generate ideas on how the intervention may be improved for future use",[133,103,40,102,36,41,34],"ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)",[135,136,137,138,139,140,141],"Anxiety disorders","Children","Adolescents","Cognitive Behavioral Therapy","Remote delivery","Internet","Internet-delivered cognitive behavioral therapy","2026-02-19",{"date":144,"type":54},"2026-02-20",{"date":146,"type":54},"2025-12-12",{"date":148,"type":22},"2027-06-01",{"name":150,"class":61},"Lund University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":168,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":62},"100472117","respiratory-training-in-the-treatment-of-transdiagnostic-pathological-anxiety-100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":159,"type":22},180,[25],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[76,163,36,41,34,164,40,165,166,167],"Trauma","Illness Anxiety Disorder","Posttraumatic Stress Disorder","Acute Stress Disorder","Adjustment Disorder With Anxious Mood",[169,170,171,172],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":175,"type":54},"2025-08-24",{"date":177,"type":54},"2022-08-22",{"date":179,"type":22},"2027-05",{"name":181,"class":61},"University of Texas at Austin",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":62},"100490845","mindful-self-compassion-for-anxiety-disorders-and-depression-100490845","NCT05671419","Mindful Self-Compassion for Anxiety Disorders and Depression","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners","75 Years",{"count":190,"type":22},40,[25],"The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.",[76,36,40,194,41,34,77],"Social Phobia","2025-06-10",{"date":197,"type":54},"2025-06-13",{"date":199,"type":54},"2022-01-16",{"date":201,"type":22},"2026-07",{"name":87,"class":61},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":62},"100576655","analyzing-the-benefits-of-using-symptoms-jit-for-in-vivo-exposure-in-anxiety-disorders-100576655","NCT06788119","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders","Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders: a Randomized Controlled Trial Using a Mixed Methods Approach","Inclusion Criteria:\n\n* Being at least 18 years or older.\n* Meeting DSM-5 diagnostic criteria (APA, 2013) for anxiety disorder, specifically specific phobia, agoraphobia, panic disorder and social phobia.\n* Being willing to follow the study conditions.\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Having another psychological problem that requires immediate attention.\n* Having current alcohol or drug dependence or abuse, psychosis or severe organic illness.\n* Currently being treated in a similar treatment program.\n* Taking anxiolytics during the study (or in the case of taking them, changing drug or dose during the study).",{"count":211,"type":22},158,[25],"The aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. The main hypotheses are:\n\n1. Both treatment conditions (CBT treatment with IVE and CBT treatment with IVE+SYMPTOMS-JIT) will show efficacy and no statistically significant differences will be found between them. The efficacy will be determined for the differences in pre-post treatment in the used outcome measures.\n2. The therapeutic gains obtained in both treatment conditions (IVE and (IVE+SYMPTOMS-JIT) will be maintained at 1-, 6-, and 12-month follow-up periods.\n3. Both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. However, IVE+SYMPTOMS-JIT will be preferred and perceived as less aversive than IVE.\n4. The main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.",[76,103,41,34,40],[135,216,217,218,219],"In vivo exposure","app","smartphone","smartwatch","2025-05-12",{"date":222,"type":54},"2025-05-16",{"date":224,"type":54},"2025-04-30",{"date":226,"type":22},"2027-12-31",{"name":228,"class":61},"Universitat Jaume I",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":70,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":245,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":4},"100448372","testing-a-precision-psychotherapy-system-for-low-income-patients-100448372","NCT05118594","Testing a Precision Psychotherapy System for Low-income Patients","Open-trial to Prospectively Test the Feasibility of a Precision Psychotherapy System for Low-income Patients","ML_LMIC","Inclusion Criteria:\n\n* Diagnoses of a depressive disorder (i.e., major depressive disorder or dysthymic disorder) or an anxiety disorder (i.e., specific phobia, social anxiety disorder, panic disorder, agoraphobia or generalized anxiety disorder) determined with the Mini-International Neuropsychiatric Interview (MINI)\n* A score of at least two (mild) in any the five items from the depression and anxiety domains of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult\n* A total family income below the poverty index threshold, determined by a Licensed Social Worker\n* Aged 18 to 65\n* Fluency in Spanish language\n* Capacity to consent\n\nExclusion Criteria:\n\n* Psychosis\n* Mania\n* Suicidal ideation with intent and\u002For plan\n* Substance abuse disorders\n* History of organic mental disease.",{"count":238,"type":22},111,[25],"The purpose of this study is to evaluate the feasibility of an evidence-based system to recommend core interventions, before the beginning of treatment, to psychotherapists treating low-income patients with depressive or anxiety disorders.",[77,242,103,40,41,34,36],"Dysthymic Disorder",[244,135],"Depressive disorders","NOT_YET_RECRUITING","2021-11-11",{"date":248,"type":54},"2021-11-18",{"date":250,"type":22},"2026-02",{"date":252,"type":22},"2026-11",{"name":254,"class":255},"National Council of Scientific and Technical Research, Argentina","OTHER_GOV"]